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Splenic Hemangiomas
Contrast-Enhanced Sonographic Findings
ocal splenic lesions are rare, occurring with a frequency of
about 0.2% on sonography.1 Hemangiomas are the most
common primary benign neoplasms of the spleen, with
prevalence ranging from 0.3% to 14% at autopsy.2–4 On gray scale
sonography, a splenic hemangioma may show the typical appear-
ance described for a liver hemangioma (a hyperechoic lesion with
well-defined margins with or without posterior wall shadowing,
usually without a vascular signal on color Doppler evaluation).4,5
Nevertheless, a splenic hemangioma may have an atypical sono-
graphic aspect, making the right diagnosis difficult.5
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Objectives—The purpose of this study was to illustrate the baseline appearance and en-
hancement patterns of splenic hemangiomas on contrast-enhanced sonography.
Methods—Two experienced radiologists retrospectively reviewed by consensus base-
line and contrast-enhanced sonographic examinations of 27 patients (14 women and 13
men; mean age, 58.7 years) with 27 splenic hemangiomas (mean size, 2 cm) confirmed
by splenectomy, biopsy, computed tomography, and magnetic resonance imaging and
follow-up.
Results—On baseline sonography, 77.8% of the lesions showed a homogeneous echo
texture that was mainly hyperechoic. Color Doppler imaging did not show any signal in
81.5% of the cases. After contrast agent injection, 59.2% of the splenic hemangiomas
showed different degrees of contrast enhancement in the arterial phase followed by
isoenhancement in the late parenchymal phase. Among these, 2 hemangiomas showed
peripheral globular enhancement in the arterial phase, followed by progressive cen-
tripetal fill-in. In 29.6% of the cases, some degree of contrast enhancement was appre-
ciable, but the hemangiomas remained substantially hypoechoic throughout the
contrast-enhanced sonographic examinations, whereas in 11.1%, the combination of
contrast enhancement in the arterial phase followed by wash-out in the late parenchy-
mal phase was evident.
Conclusions—Isoechogenicity to spleen parenchyma in all phases is the most frequent
typical enhancement pattern of splenic hemangiomas observed on contrast-enhanced
sonography. Nevertheless, these lesions may show atypical contrast enhancement pat-
terns; therefore, further assessment with cross-sectional techniques is needed. 
Key Words—contrast-enhanced sonography; spleen; splenic hemangioma; splenic neo-
plasms
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Contrast-enhanced sonography represents a substan-
tial breakthrough in sonography, and it is being increas-
ingly used for the evaluation of focal liver lesions.6 The
unique feature of contrast-enhanced sonography of non-
invasively assessing perfusion throughout the vascular
phase in real time has led to a dramatic improvement in
the diagnostic accuracy of sonography for detection and
characterization of focal liver lesions as well as guidance
and evaluation of responses to therapeutic procedures.7,8
Recently, several authors have considered the spleen
as one of the new promising fields of application of 
contrast-enhanced sonography by showing that a sulfur
hexafluoride–based contrast agent produces spleen-
 specific enhancement that lasts longer (up to 5 minutes)
than typical blood pool and liver enhancement phases.9–11
Hence, considering that the spleen is infrequently the
primary site affected by disease and that splenic lesions are
somewhat rare, the radiologist is unlikely to be as familiar
with these latter lesions as with those of the liver.12 Conse-
quently, the aim of this study was to describe baseline
sonographic appearance and contrast-enhanced sono-
graphic patterns of splenic hemangiomas. 
Materials and Methods
Patient Population
All patients gave their full informed consent before contrast-
enhanced sonography, and the procedure followed was in
accord with the Declaration of Helsinki.13 Baseline and 
contrast-enhanced sonographic examinations of 27 patients
(14 women and 13 men; age range, 28–76 years; mean,
58.7 years) referred to our institution between June 2003
and September 2011 with 27 splenic hemangiomas (size
range, 0.8–10.1 cm; mean ± SD, 2 ± 2.1 cm) were retro-
spectively evaluated. The patients’ records were retrieved
from our institutional radiologic database on the basis of
the following inclusion criteria: (1) the presence of at least
1 splenic hemangioma with an adequate reference stan-
dard; and (2) the presence in our picture archiving and
communication system (Impax; Agfa-Gevaert, Milan, Italy)
of either a baseline or a contrast-enhanced sonographic
study aimed at characterizing each single lesion.
Sixteen of 27 splenic hemangiomas were discovered
during sonographic examinations performed for diffuse ab-
dominal pain (n = 13), left abdominal discomfort (n = 2)
and trauma (n = 1), and the remaining 11 lesions were de-
picted during computed tomographic (CT) examinations
performed for cancer staging (n = 10: 5 hepatocellular car-
cinomas, 1 gastric cancer, 1 large-bowel cancer, 1 breast
cancer, 1 cervical cancer, and 1 renal cancer) or to charac-
terize an indeterminate focal liver lesion (n = 1). Twenty-
five lesions underwent imaging follow-up (range, 12–48
months; mean, 14.5 months).
Sonographic Technique
Sonographic examinations were performed by the same
radiologist (>5 years of experience in conventional and
contrast-enhanced sonography), who was aware of the pa-
tients’ clinical histories and used an iU22 scanner (Philips
Healthcare, Bothell, WA) equipped with a 5–2-MHz con-
vex array probe and pulse inversion harmonic imaging soft-
ware. The study was performed under baseline conditions,
including color and power Doppler analysis, and after in-
travenous administration of 2.4 and 4.8 mL (in patients
with a normal-sized spleen [n = 25] and splenomegaly
[long axis of the spleen >130 mm; n = 2], respectively) of
a sulfur hexafluoride–filled microbubble-based contrast
agent (SonoVue; Bracco SpA, Milan, Italy) in a rapid bolus
followed by a 5-mL sterile saline flush in the antecubital
vein with a 20-gauge needle.10,14,15
The ultrasound beam was focused immediately below
the region of interest. A low frame rate (5 Hz) and a very
low mechanical index (0.05–0.09) were used. Once set,
the sonographic parameters, such as the focal zone, time-
gain compensation, and mechanical index, were not
changed throughout the study. Each lesion was scanned
for up to 5 minutes, and digital cine clips were registered 5
to 30 seconds (arterial phase), 60 to 90 seconds (interme-
diate parenchymal phase), and 180 to 300 seconds (late
parenchymal phase) from the beginning of the contrast
agent bolus injection.10,16–18 All cine clips were digitally
stored as raw data in a personal computer–based worksta-
tion connected to the ultrasound unit via a standard Eth-
ernet link.
On-site Image Analysis
The examiner measured and located each lesion in the
superior, middle, or inferior third of the spleen and sub-
jectively evaluated the baseline findings. The following
parameters were considered: (1) baseline echogenicity
of the lesions with respect to the remaining splenic
parenchyma, defined as hyperechoic, hypoechoic, iso echoic,
and mixed; (2) echo texture of the lesions, described as
homogeneous and inhomogeneous; (3) borders, consid-
ered well or poorly defined; (4) lesion contours, evaluated
as smooth or lobulated depending on margins that were
round or lobular; (5) the presence and type (arterial or ve-
nous) of any intralesional or peripheral flow on the baseline
color and power Doppler examination; and (6) the pres-
ence of calcifications.2
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Off-site Image Analysis
All contrast-enhanced sonographic examinations were re-
viewed by consensus by 2 experienced radiologists (>10
years of experience in contrast-enhanced sonography) not
involved in the scanning and blinded to the clinical data and
the final diagnosis. Two consecutive interpretation sessions
with a 7-day interval to avoid recall bias were held to com-
plete the review process of all patients’ contrast-enhanced
sonographic examinations. The readers assessed the con-
trast enhancement behavior of each lesion in comparison
with adjacent spleen parenchyma after SonoVue injection.
Changes in the echogenicity and enhancement patterns
after contrast medium injection, subjectively categorized as
follows: (1) peripheral globular (enhancing peripheral
nodular areas); (2) rimlike (continuous ring of peripheral
enhancement); (3) hyperechoic (higher echogenicity than
the spleen); (4) hypoechoic (lower echogenicity than the
spleen); and (5) isoechoic (similar echogenicity relative to
the spleen). The progression of contrast enhancement (cen-
tripetal or centrifugal) was also considered. In particular, at
retrospective off-site analysis, the readers were asked to iden-
tify a splenic hemangioma on the basis of the following crite-
ria: (1) a constantly homogeneously isoenhancing lesion;
and (2) a peripheral globular pattern followed by progressive
centripetal fill-in.10,17
Reference Standard 
The final diagnosis was obtained by means of contrast-
 enhanced multidetector computed tomography (n = 17),
magnetic resonance imaging (MRI; n = 13), biopsy (n =
2), and splenectomy (n = 2). Four patients underwent
splenectomy and biopsy, respectively, within 1 week after
contrast-enhanced sonography.
Strict imaging criteria, comparable with those de-
scribed for liver hemangioma, were used, including the fol-
lowing: (1) nodular peripheral enhancement followed by
centripetal fill-in; (2) isoattenuation to blood vessels; (3)
high signal intensity on T2-weighted MR images; (4) ho-
mogeneous enhancement on delayed MR images; and (5)
lack of a 6- to 12-month increase in size.2–4,17,19–25
Multidetector CT studies were performed using a 64-
row multidetector scanner (Brilliance; Royal Philips Elec-
tronics, Eindhoven, the Netherlands), acquiring images
before and after the administration of 1.5-mL/kg iomeprol
(400 mgI/mL; Iomeron; Bracco SpA) at a flow rate of 4
mL/s by an automated power injector. The examination was
performed using a bolus-tracking technique, and 3 scans were
performed with delays of 20 to 25 seconds (arterial phase), 45
to 50 seconds (venous phase), and 180 to 300 seconds (de-
layed phase). Further late phases were acquired if necessary.
Magnetic resonance examinations were performed
with a 1.5-T scanner (Signa Excite; GE Healthcare, Mil-
waukee, WI). The protocol included a precontrast axial
T1-weighted gradient echo sequence, a T2-weighted 
single-shot fast spin echo sequence, a T2-weighted fast
spin echo sequence, an unenhanced and contrast-en-
hanced T1-weighted volumetric sequences. A dynamic
study was obtained after intravenous administration of a
bolus of 0.2-mL/kg gadobenate dimeglumine (Multi-
Hance; Bracco SpA) injected at a flow rate of 2 mL/s fol-
lowed by 20 mL of a sterile saline solution using an
automated injector. Images were acquired using an auto-
mated bolus detection technique during the arterial (14
seconds after bolus detection), venous (50 seconds), equi-
librium (3 minutes), and late (5–20 minutes) phases.
Multidetector CT and MR images were evaluated
using the Impax picture archiving and communication sys-
tem. The interval between contrast-enhanced sonography
and CT/MRI was 1 week at the latest for each patient.
Statistical Analysis
Statistical analysis was performed by a biostatistician in-
volved in the study design using a computer software
package (Intercooled Stata for Windows, version 9.2;
StataCorp, College Station, TX). The association between
a typical or an atypical pattern on contrast-enhanced sonog-
raphy and the size (≤3 and >3 cm), baseline echogenicity
(hypoechoic, isoechoic, hypoechoic, or mixed), and echo
texture (homogeneous or inhomogeneous) on gray scale
sonography was evaluated. To assess the association be-
tween categorical variables, the χ2 test or Fisher exact test
was used as appropriate. Statistical significance was con-
sidered to be present at P < .05.
Results
On-site Image Analysis
Table 1 summarizes the general and baseline sonographic
features of the 27 splenic hemangiomas, located in the su-
perior (n = 8), middle (n = 8), or inferior (n = 9) third of
the spleen. Furthermore, 1 lesion involved both the supe-
rior and middle thirds of the spleen, and the last 1 involved
almost the whole spleen parenchyma.
On baseline sonography, 21 of the 27 hemangiomas
(77.8%) showed a homogeneous echo texture, hyper -
echoic (n = 15), hypoechoic (n = 4), and isoechoic (n = 2),
whereas 6 (22.2%) had an inhomogeneous echo texture
with a mixed appearance (n = 2, 1 of which had intrale-
sional anechoic areas of a few millimeters) or mainly hy-
poechoic (n = 3) and hyperechoic (n = 1). Calcifications
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were not observed within any hemangioma. All of the he-
mangiomas showed round contours, and 26 (96.3%) had
well-defined borders. Color Doppler evaluation did not
show any signal in 22 (81.5%) of the hemangiomas. Two
had perilesional vascular signals with arterial (n = 1) or ve-
nous flow (n = 1) on pulsed Doppler analysis. In 2 cases
(7.4%), both perilesional and intralesional vascular signals
with arterial (n = 1) and arterial-venous (n = 1) flow were
observed and, finally, the remaining case (3.8%) had in-
tralesional arterial flow.
Off-site Image Analysis
Table 2 summarizes the contrast-enhanced sonographic
patterns of the splenic hemangiomas. After contrast agent
injection, 16 of 27 hemangiomas (59.2%) showed different
degrees of contrast enhancement (isoechoic, hyperechoic,
and peripheral globular patterns) in the arterial phase fol-
lowed by isoenhancement relative to splenic parenchyma
in the late parenchymal phase. Among these, 2 (7.4%)
Taibbi et al—Contrast-Enhanced Sonography of Splenic Hemangiomas
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Table 1. General and Baseline Sonographic Features of 27 Splenic Hemangiomas
Size, Color Pulsed Reference Follow-
Lesion cm Location Echo Texture Borders Contour Echogenicity Doppler Doppler Standard up, mo
1 3 Superior third Inhomogeneous Well-defined Round Mixed Peripheral Venous Biopsy 12
2 1 Inferior third Inhomogeneous Well-defined Round Hypoechoic No NA CT 24
3 8 Superior-middle Homogeneous Well-defined Round Isoechoic Intralesional/ Arterial Histology NA
third peripheral
4 10.1 Whole spleen Homogeneous Well-defined Round Hyperechoic Intralesional/ Arterial/ Histology NA
peripheral venous
5 2.8 Inferior third Inhomogeneous Well-defined Round Hypoechoic Intralesional Arterial CT 24
6 0.8 Inferior third Homogeneous Well-defined Round Hyperechoic No NA CT 12
7 0.9 Inferior third Homogeneous Well-defined Round Hyperechoic No NA CT/MRI 13
8 1 Inferior third Homogeneous Well-defined Round Hyperechoic No NA CT/MRI 15
9 1.1 Inferior third Homogeneous Well-defined Round Hyperechoic No NA CT 15
10 1.3 Superior third Homogeneous Well-defined Round Hyperechoic No NA CT 13
11 1.5 Inferior third Homogeneous Well-defined Round Hyperechoic No NA CT/MRI 12
12 1.8 Superior third Homogeneous Well-defined Round Hyperechoic No NA CT 12
13 1 Inferior third Homogeneous Well-defined Round Hypoechoic No NA CT 15
14 2.9 Superior third Homogeneous Well-defined Round Hyperechoic No NA CT/MRI 48
15 1.8 Superior third Inhomogeneous Well-defined Round Hypoechoic No NA CT/MRI 12
16 1 Inferior third Homogeneous Well-defined Round Hypoechoic Peripheral Arterial CT/MRI 13
17 1.2 Middle third Homogeneous Well-defined Round Hyperechoic No NA CT/MRI 12
18 2.5 Middle third Inhomogeneous Poorly defined Round Mixed No NA MRI 12
19 0.9 Middle third Homogeneous Well-defined Round Hyperechoic No NA CT 12
20 1.2 Superior third Homogeneous Well-defined Round Hypoechoic No NA MRI 12
21 1 Middle third Inhomogeneous Well-defined Round Hyperechoic No NA MRI 12
22 1.8 Middle third Homogeneous Well-defined Round Hyperechoic No NA Biopsy 12
23 2 Superior third Homogeneous Well-defined Round Hyperechoic No NA MRI 48
24 1.4 Middle third Homogeneous Well-defined Round Hyperechoic No NA MRI 12
25 1 Middle third Homogeneous Well-defined Round Hypoechoic No NA MRI 12
26 1.3 Superior third Homogeneous Well-defined Round Isoechoic No NA CT 15
27 1 Middle third Homogeneous Well-defined Round Hyperechoic No NA CT 12
CT indicates computed tomography; MRI, magnetic resonance imaging; and NA, not applicable.
Table 2. Analysis of Contrast Enhancement Patterns of 27 Splenic He-
mangiomas After SonoVue Administration
Intermediate Late
Size, Arterial Parenchymal Parenchymal
Lesions, n cm Phase Phase Phase
9 0.8–1.8 (1.2) Isoechoic Isoechoic Isoechoic
1 3.0 Nodular Centripetal Complete
peripheral fill-in fill-in
1 1.0 Nodular Centripetal Incomplete
peripheral fill-in fill-in
2 1.3–8.0 (4.6) Hyperechoic Isoechoic Isoechoic
1 10.5 Hyperechoic Hyperechoic Isoechoic
2 1–1.4 (1.2) Hypoechoic Isoechoic Isoechoic
8 0.9–2.9 (1.6) Hypoechoic Hypoechoic Hypoechoic
1 1.8 Hyperechoic Isoechoic Hypoechoic
1 1.0 Isoechoic Hypoechoic Hypoechoic
1 2.8 Hyperechoic Hypoechoic Hypoechoic
Values are range (mean) where applicable.
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showed peripheral globular enhancement in the arterial
phase, followed by progressive centripetal fill-in, which was
complete in 1 of 2 cases (Figure 1).
Eight of the 27 hemangiomas (29.6%) showed some
degree of contrast enhancement but remained substan-
tially hypoechoic throughout the contrast-enhanced sono-
graphic examinations (Figure 2), whereas 3 (11.1%)
showed a combination of contrast enhancement in the ar-
terial phase followed by wash-out in the late parenchymal
phase (Figure 3).
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Taibbi et al—Contrast-Enhanced Sonography of Splenic Hemangiomas
Figure 1. Splenic hemangioma in a 68-year-old man with hepatocellular carcinoma. A, Oblique left subcostal baseline image showing a lesion with
a mixed echo texture measuring 3 cm in the superior third (arrow). B–D, Fifteen seconds after SonoVue injection, the lesion shows peripheral glob-
ular enhancement (B, arrow) followed by progressive and complete centripetal fill-in at 40 seconds (C, arrow), becoming isoechoic with respect to
the surrounding splenic parenchyma in the late phase (D).
A B
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Statistical analysis showed no significant association
between the contrast-enhanced sonographic pattern and
size (P = .497), echo texture (P > .99), or echogenicity 
(P = .851). 
Discussion
Hemangiomas are the most common benign neoplasms
of the spleen, but although they are found in up to 14% of
patients in autopsy series, they are less frequently detected
on imaging examinations.3 Usually, this vascular neoplasm
Taibbi et al—Contrast-Enhanced Sonography of Splenic Hemangiomas
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Figure 2. Splenic hemangioma in a 73-year-old woman with hepatocellular carcinoma. A, Oblique left subcostal baseline image showing a homo-
geneously hyperechoic lesion measuring 1 cm in the middle third (arrow). B–D, After SonoVue injection, the lesion appears constantly hypovascu-
lar during all phases (arrows) (continued). 
A B
C D
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is depicted in adults aged 30 to 50 years with equal fre-
quency among men and women.4 Splenic hemangiomas
present as single or multiple masses and may be part of
generalized angiomatosis as Gorham disease, Klippel-
 Trènaunay-Weber syndrome, Sturge-Weber syndrome,
and Von Hippel-Lindau disease.19,26 Although most
splenic hemangiomas is asymptomatic, anemia, thrombo-
cytopenia, and coagulopathy could be associated with large
lesions, likely secondary to sequestration of red blood cells
and platelets and consumption of clotting factors.27
Rarely, the clinical presentation can also be acute because
of spontaneous splenic rupture with consequent hemo-
peritoneum.3 However, splenic hemangiomas are often
discovered in asymptomatic patients as incidental findings
during abdominal imaging procedures performed for other
reasons, as occurred in our series.4
J Ultrasound Med 2012; 31:543–553 549
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Figure 2. (continued) E, T2-weighted axial fast spin echo image show-
ing a homogeneously hyperintense round lesion (arrow). F and G, On
contrast-enhanced magnetic resonance imaging obtained in the arterial
phase, the lesion is hypointense (F, arrow) but shows complete fill-in 10
minutes after contrast medium injection (G, arrow).
E
F G
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On sonography, a splenic hemangioma may appear
either as a well-defined hyperechoic lesion, usually smaller
than 2 cm and corresponding to the solid form, or as a large
complex mass, intrasplenic or pedunculate, containing
solid and cystic areas filled with serous or hemorrhagic fluid
due to necrosis.4 Nevertheless, the variability of sono-
graphic appearances of splenic hemangiomas is reported
to be greater than in the liver.12 Furthermore, sonographic
appearances of spleen disease are rather nonspecific, and
differentiation between benign and malignant lesions is
Taibbi et al—Contrast-Enhanced Sonography of Splenic Hemangiomas
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Figure 3. Splenic hemangioma in a 28-year-old man found during a sonographic examination performed for trauma. A, Oblique left subcostal base-
line image showing a homogeneously hypoechoic lesion measuring 2.8 cm in the inferior third. B–D, Thirty seconds after SonoVue injection, the le-
sion presents as hypervascular (B, arrow) but appears hypovascular with respect to the surrounding splenic parenchyma in both the intermediate
(C) and late (D) phases.
A B
C D
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often difficult. The latter are more likely multifocal or dif-
fuse, characterized by rapid growth and the presence of 
extrasplenic abdominal masses.12,28 In our series, on gray
scale sonography, less than two-thirds of splenic heman-
giomas showed a typical hyperechoic appearance with well-
defined borders, suggesting the diagnosis of a hemangioma,
whereas the remaining 12 (44.4%) were otherwise unde-
termined.5
According to previously published data reporting that
in most splenic hemangiomas, the vascularization is poor
on color Doppler evaluation, in our series, 22 of the 27 
hemangiomas (81.5%) did not show any vascular signal,
confirming that the practical utility of color Doppler im-
aging in characterizing splenic lesions is quite low.1,18 How-
ever, the absence of major intralesional vessels may be
helpful in differentiating splenic hemangiomas either from
malignant lesions, such as lymphomas and metastasis, and
other benign masses, such as hamartomas, in which color
Doppler sonography usually depicts a hypervascular pat-
tern.4,17 Contrast-enhanced sonography represents a reli-
able, safe, and cost-saving technique with diagnostic
accuracy similar to that of CT and MRI performed with
state-of-the-art scanners in the characterization of focal
liver lesions.29 In particular, a sulfur hexafluoride–based
contrast agent might not be necessarily a pure vascular
agent, as initially deemed, because it seems to have a
marked spleen-specific uptake, maybe in the reticuloen-
dothelial system or sinusoids. Therefore, spleen enhance-
ment after SonoVue injection lasts longer than liver
enhancement, usually greater than 5 minutes.11,30
In our experience, after SonoVue administration, 11 of
the 27 splenic hemangiomas (40.7%) showed contrast 
enhancement patterns suggestive of hemangiomas.10,31
In particular, the most frequent enhancement pattern of
the splenic hemangiomas depicted on contrast-enhanced
sonography was isoechogenicity to spleen parenchyma in
all phases (one-third of all splenic hemangiomas). This 
pattern is different from the typical contrast enhancement
pattern of liver hemangiomas but is considered diagnostic
of splenic hemangiomas.10,31 Only 2 splenic hemangiomas
showed the well-known peripheral globular enhancement
followed by progressive centripetal fill-in.
This latter pattern is peculiar but less frequently 
observed in splenic hemangiomas than in liver heman-
giomas.15,19 In fact, Stang et al17 never observed this con-
trast enhancement behavior in their study population
including 26 splenic hemangiomas, whereas von Herbay
et al16 depicted it in 2 of their 3 splenic hemangiomas. 
Interestingly, 5 other splenic hemangiomas showed sus-
tained contrast enhancement in the late parenchymal
phase, a pattern suggesting benignity. By contrast, 11 of
the 27 splenic hemangiomas (40.7%) in our series showed
a hypovascular appearance in the late parenchymal phase
on contrast-enhanced sonography, 3 of which showed late
wash-out. This finding is quite unusual, although it has also
been reported in liver hemangiomas, suggests malignity,
and, hence, may be confounding for the radiologist.17,32
Our study confirms that even in the spleen, this contrast
enhancement pattern is not always suggestive of malig-
nancy.32 In this regard, von Herbay et al,16 comparing be-
nign and malignant spleen lesions on contrast-enhanced
sonography, confirmed that a persistent hypoechoic as-
pect in both the early and parenchymal phases was highly
suspicious of benign lesions, and we observed this behav-
ior in about one-third of our cases.
In this latter case, a further imaging technique may be
mandatory for lesion characterization.4 Actually, CT and
MRI showed complete fill-in in all 11 splenic heman-
giomas in our study presenting on contrast-enhanced
sonography as hypoechoic masses in the late parenchymal
phase (as shown in Figure 2). Some hypotheses can be
made to explain this already reported atypical behavior.18,33
First, as in the liver, splenic hemangiomas may contain
large vascular channels and, consequently, internal slow
flow. Hence, the ability to observe progressive and com-
plete fill-in may require even longer than 15 minutes,
and CT and MRI best suited for this purpose, probably
because of the longer half-life of the contrast media.34
Second, the spleen is a highly vascularized organ, and on
contrast-enhanced sonography, even vascular lesions may
appear hypoechoic with respect to the surrounding splenic
parenchyma. Finally, as already reported, SonoVue shows
high spleen-specific enhancement because it seems to 
accumulate within the reticuloendothelial system with
prolonged enhancement of parenchyma. The absence of
reticuloendothelial cells within the hemangioma could ex-
plain the difference in contrast enhancement between the
latter and the normal splenic parenchyma. However, in our
study, statistical analysis showed no significant association
between the enhancement pattern on contrast-enhanced
sonography, either typical or atypical, and size, echo tex-
ture, or echogenicity.
Our study had some limitations. First, the final diag-
nosis was established by histologic evaluation in only 4
cases. However, considering ethical reasons and accord-
ing to literature, the diagnosis of a splenic hemangioma can
be confidently obtained when clinical, biochemical, and
imaging criteria are met, recommending follow-up of pa-
tients with asymptomatic splenic hemangiomas at least
until the lesions are determined to be of a constant size,
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and the lesions included in our study did not show any size
changes during follow-up.2,3,35–37 Second, off-site imaging
analysis was performed by consensus, and interobserver
agreement was not assessable. Finally, our study popula-
tion was limited, but that factor can be justified by the rar-
ity of the lesions.
In conclusion, in our experience, isoechogenicity to
spleen parenchyma in all phases is the most frequent typi-
cal enhancement pattern of splenic hemangiomas on
contrast-enhanced sonography. Nevertheless, these lesions
may show atypical contrast enhancement patterns more
frequently than their liver counterparts. When a splenic
mass is discovered during a sonographic examination per-
formed for other reasons, in the absence of a clinical his-
tory suggesting a malignant nature, a primary benign
vascular neoplasm should be considered, and a heman-
gioma is the most common focal splenic lesion. Contrast-
enhanced sonography can be considered an effective tool
for the diagnosis only when showing typical contrast en-
hancement patterns. Otherwise, further assessment with
cross-sectional techniques is needed for characterization. 
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